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ABSTRACT: The purpose of this work was the assembly of
multicomponent nano-bioconjugates based on mesoporous silica
nanoparticles (MSNs), proteins (bovine serum albumin, BSA, or
lysozyme, LYZ), and gold nanoparticles (GNPs). These nano-
bioconjugates may ﬁnd applications in nanomedicine as
theranostic devices. Indeed, MSNs can act as drug carriers,
proteins stabilize MSNs within the bloodstream, or may have
therapeutic or targeting functions. Finally, GNPs can either be
used as contrast agents for imaging or for photothermal therapy.
Here, amino-functionalized MSNs (MSN−NH2) were synthe-
sized and characterized through various techniques (small angle
X-rays scattering TEM, N2 adsorption/desorption isotherms, and
thermogravimetric analysis (TGA)). BSA or lysozyme were then
grafted on the external surface of MSN−NH2 to obtain MSN−BSA and MSN−LYZ bioconjugates, respectively. Protein
immobilization on MSNs surface was conﬁrmed by Fourier transform infrared spectroscopy, ζ-potential measurements, and
TGA, which also allowed the estimation of protein loading. The MSN−protein samples were then dispersed in a GNP solution
to obtain MSN−protein−GNPs nano-bioconjugates. Transmission electron microscopy (TEM) analysis showed the occurrence
of GNPs on the MSN−protein surface, whereas almost no GNPs occurred in the protein-free control samples. Fluorescence and
Raman spectroscopies suggested that proteins−GNP interactions involve tryptophan residues.
1. INTRODUCTION
Nanomedicine is a branch of medicine based on the use of
diagnostic and therapeutic nanodevices.1−3 Nanodevices take
advantage of the speciﬁc physicochemical properties of matter
at the nanoscale and thus behave diﬀerently from their bulk
counterparts.4 There is a wide range of biomedical nano-
devices, and various combinations of them exist. A relevant
example is provided by mesoporous silica nanoparticles
(MSNs),5 which are very promising drug delivery systems.6−9
MSNs, besides being highly stable and biocompatible,10
combine a high external-surface-to-volume ratio with extended
inner surface area and tailored porosity. These features can be
exploited for the immobilization and the controlled release of
drugs11−18 or biological macromolecules.19−22 External surface
functionalization plays a key role to promote targeting13 and to
enhance the biocompatibility of MSNs.23,24 Indeed, if the
external surface of MSNs is functionalized with a charged
biopolymer, as for instance hyaluronic acid, a high degree of
cell internalization, which is likely mediated by a CD44
receptor in a peculiar kind of cell membranes, can be
observed.25,26
Several previous studies focused on the interactions between
mesoporous silica-based materials and enzymes/proteins.27−29
These bioconjugates can be engineered for biocatalytic or
biomedical applications depending on the fact that either an
enzyme or a therapeutic protein is used.30−32 Micrometric
mesoporous silica particles, such as SBA-15 (pore size 6−9
nm), can adsorb proteins/enzymes on the internal surface,33,34
whereas MSNs of the type MCM-41 (pore size ≈ 2 nm)
mainly address protein adsorption on the external surface.
Coating by speciﬁc proteins is used to stabilize nanoparticles in
body ﬂuids and thus MSNs can be injected in the
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bloodstream.35,36 To this purpose, blood plasma proteins, such
as serum albumins, are the most widely used.37,38 Other
proteins, such as antibodies, as well as nucleic acids or simple
peptides, are able to carry out a targeting function,39,40
dragging nanoparticles to target receptors of cells or organs
and, therefore, reducing side eﬀects and administration
doses.41,42 Additionally, plasma proteins are naturally adsorbed
on nanoparticle surfaces forming a “protein corona”.26,43 This
natural phenomenon aﬀects the surface charge and hence the
colloidal stability of the nanoparticles, which can either be
favored or unfavored depending, for example, on the sign of
the electric charge of the externally grafted biopolymer.26
Gold nanoparticles (GNPs) are other nanodevices widely
exploited in nanomedicine. GNPs are characterized by a
surface plasmon frequency in the visible range, which makes
them suitable for a wide range of applications, ranging from
therapeutic treatments (i.e., photothermal therapy44) to
diagnostic imaging or, more interestingly, “theranostics”,
which is the combination of therapy and diagnostics.45−47
The purpose of this work is to combine MSNs, proteins, and
GNPs within a single multicomponent system (Scheme 1).
Zhan et al. used mesoporous silica-encapsulated gold nanorods
bioconjugated with antibodies to create a multifunctional
system for imaging of cancer cells.48 Croissant et al. prepared a
pH-responsive drug delivery system constituted by negatively
charged BSA−gold clusters (AuNC@BSA), which interacted
with the positively charged amino-functionalized mesoporous
silica (MSN−NH3+) through electrostatic forces. At acidic pH,
the AuNCs@BSA desorbed from the silica surface, thus
allowing the release of the drug molecules by the pores.10
Here, we use MCM-41-type MSNs due to their ability to act as
potential nanocarriers. MSNs are covalently coated by two
model proteins, namely, bovine serum albumin (BSA) to
provide stability and biocompatibility to the MSNs within the
hematic ﬂuid and lysozyme (LYZ) as a model antimicrobial
protein.49,50 In addition, 20 nm nearly spherical GNPs are
adsorbed on the protein-conjugated MSNs. The resulting
multicomponent nano-bioconjugates are characterized by
several physicochemical techniques, namely, small angle X-
rays scattering (SAXS), transmission electron microscopy
(TEM), electrophoretic light scattering (ELS), N2-physisorp-
tion, thermogravimetric analysis (TGA), and Fourier transform
infrared (FTIR) spectroscopy. In particular, ﬂuorescence
spectroscopy and surface-enhanced Raman spectroscopy
(SERS) allowed to shed light on the mechanism of protein−
GNP interaction. The assembled multicomponent silica−
protein−gold nano-bioconjugate represents a prospective
nanodevice for theranostic applications.
2. RESULTS AND DISCUSSION
2.1. Characterization of MSN−NH2. Amino-function-
alized mesoporous silica nanoparticles (MSN−NH2) were
synthesized as a ﬁrst step in the design of multicomponent
nano-bioconjugates. Figure 1 shows the structural and textural
characterization of an MSN−NH2 sample. The TEM image
displays the occurrence of nearly spherical silica particles with a
size of about 100−120 nm and with a well-deﬁned porosity
consisting of parallel channels with a hexagonal arrangement of
pores (Figure 1A). The SAXS pattern of the MSN−NH2
sample, shown in Figure 1B, displays the typical pattern
observed for hexagonal (P6mm) mesoporous structures,
represented by an intense peak, due to the reﬂection of 1 0
plane, and two weak peaks due to the reﬂection of 1 1 and 2 0
planes, respectively. The resulting lattice parameter, a, has a
value of 46.5 Å. N2 adsorption/desorption isotherm is of a type
IV (Figure 1C), resulting in a surface area (SBET) of 942 m
2/g
and a pore volume (Vp) of 1.08 cm
3/g. Pore size distribution
(Figure 1D) has a maximum at 25.8 Å (Table S1, Supporting
Information).
Thermogravimetric analysis (TGA) of the MSN−NH2
sample was then carried out. Curves in Figure 2 show that
MSN−NH2 has a mass loss at about 100 °C, attributed to the
loss of adsorbed water, and then an additional mass loss above
Scheme 1. Assembly of the MSN−Protein−GNP Nano-Bioconjugatesa
aThe MSN surface is functionalized with aminopropyltriethoxysilane (APTES) to obtain MSN−NH2. Proteins (BSA or lysozyme) are grafted, by
means of glutaraldehyde, on the external surface of MSN−NH2 to obtain MSN−protein bioconjugates. The MSN−protein samples are dispersed
in a gold nanoparticle (GNP) solution to obtain MSN−protein−GNPs nano-bioconjugates. TEM images show the occurrence of GNPs on the
MSN−protein surface, whereas almost no GNPs occur in the protein-free control samples.
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200 °C (5.7%). This conﬁrms the occurrence of organic
functional groups on the mesoporous silica surface.
2.2. Characterization of MSN−NH2−Protein Nano-
Bioconjugates. Amino-functionalized MSNs were conjugated
with BSA and lysozyme proteins using glutaraldehyde as the
linker. MSN−protein conjugation was qualitatively assessed by
FTIR spectroscopy and quantitatively by TGA.
Figure S1 (Supporting Information) shows the FTIR spectra
of MSN−BSA and MSN−LYZ conjugates. Both samples show
a peak at 1642 cm−1 due to amide I, typical of the CO
stretching of peptide bonds.26 Usually, proteins adsorbed on
mesoporous silica show a more intense amide I band and a less
intense amide II band.31 Here, the low intensity of amide I and
the absence of the amide II peak are likely due to a low protein
loading. This result is expected. Indeed, MSNs pore diameter
(about 2 nm) is smaller than lysozyme (3.8 nm)51 and BSA
(7.2 nm)52 size; thus, adsorption can occur only at the external
surface of MSNs, which is only a small fraction of the whole
surface area.
Figure 2 shows the mass loss (%) proﬁles obtained at
temperatures above 200 °C, which can be ascribed to the
burning of organics (mass loss % values obtained at
temperatures <200 °C are associated with the loss of water).
Considering the progressive increase in mass loss at the
diﬀerent steps of bioconjugation, the amount of adsorbed
proteins was calculated to be 55 and 29 mg/g for lysozyme
(MSN−LYZ) and BSA (MSN−BSA), respectively (Table 1).
These low loadings are consistent with FTIR spectra in Figure
S1. Table 1 reports TGA and ζ-potential data also for the
glutaraldehyde−MSN conjugate (MSN−GA) to describe the
changes in mass loss and surface charge during the various
steps.
Electrophoretic light scattering (ELS) technique was used to
measure ζ-potential (ζ) values of MSN-based samples prior to
and after protein immobilization at two diﬀerent pH values,
neutral (pH = 7) and acidic (pH = 4). The acidic value of pH
was chosen to provide further proof of MSNs surface
modiﬁcation due to the diﬀerent responses of MSN−NH2,
MSN−BSA, and MSN−LYZ to pH changes. As expected, we
found a highly positive ζ at pH 4 (+31 mV) and an almost
neutral value at pH 7 (+2 mV) for MSN−NH2. A similar trend
is expected for MSN−LYZ samples due to the high isoelectric
point (IEP ≈ 11) of lysozyme. Finally, due to IEP (≈4.7) of
BSA, we found a sign change for ζ going from pH 7 (−12 mV)
to pH 4 (+18 mV). Hence, ζ values listed in Table 1 are
consistent with the occurrence of a layer of BSA and LYZ
proteins covering the MSN particle surface.
2.3. TEM Characterization of MSN−Proteins−GNPs
Nano-Bioconjugates. Results described in the previous
paragraph, particularly, the change of ζ values, demonstrate
that BSA and lysozyme proteins were successfully immobilized
on the external MSNs surface. The occurrence of adsorbed
proteins on the surface is particularly important to achieve the
goal of this work, that is, the realization of nano-bioconjugates
constituted by MSN−protein−GNPs. This was done by
dispersing MSN−protein conjugates in a solution of colloidal
gold nanoparticles, as described in Section 2.2. The obtain-
ment of the nano-bioconjugates was then conﬁrmed by TEM
analysis. Figure 3 shows the TEM images of MSN samples
treated with GNPs in the presence of immobilized proteins on
the surface. Representative TEM images of control samples
where protein-free MSN was treated with GNPs are reported
in Figure S2.
Figure 1. Characterization of MSN−NH2 by (A) TEM, (B) SAXS,
(C) N2-physisorption isotherm, and (D) pore size distribution.
Figure 2. Thermogravimetric analysis. Mass loss (%) proﬁles as a
function of the temperature of MSN−NH2, MSN−GA, MSN−LYZ,
and MSN−BSA samples.
Table 1. Mass Loss % Values Obtained by Thermogravimetric Analysisa
mass loss (%) ζ (mV)
sample T < 200 °C T > 200 °C bpH = 4 cpH = 7 loading (mg g−1) molar ratio (mol g−1)
MSN−NH2 7.08 5.58 +31 ± 1 +2 ± 2 56 9.66 × 10−4 (MM−C3H6−NH2 = 58 g mol
−1)
MSN−GA 9.76 14.07 +8 ± 1 −2 ± 1 85d 8.49 × 10−4 (MMGA = 100.11 g mol−1)
MSN−BSA 11.22 16.95 +18 ± 2 −12 ± 1 29e 4.36 × 10−7 (MMBSA = 66463 g mol−1)
MSN−LYZ 8.15 19.53 +29 ± 2 +1 ± 1 55e 1.90 × 10−5 (MMLYS = 14400 g mol−1)
aζ-Potential (ζ) values of functionalized MSN samples after each step of surface functionalization. TGA and ζ data are listed also for the MSN−
glutaraldehyde intermediate (MSN−GA). bCitrate buﬀer 0.1 M. cPhosphate buﬀer 0.1 M. d(mass loss %) (mass loss %)
100
MSN GA MSN NH2−− − (T > 200 °C).
e(mass loss %) (mass loss %)
100
MSN PROTEIN MSN GA−− − (T > 200 °C).
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In particular, the nanostructures obtained by mixing a GNP
solution with MSN−BSA and MSN−LYZ are shown in Figure
3a−f and a′−f′, respectively. Interestingly, in this case, TEM
images also allow the proteins attached to the silica surface to
be located, as the presence of GNPs on the silica surface
indirectly indicates the presence of proteins at the same site.53
It can be observed that various GNPs, which appear as dark
dots, are in contact with the MSNs surface. On the contrary,
Figure 3. TEM images of (a−f) MSN−BSA and (a′−f′) MSN−LYZ treated with GNPs. Control sample (protein-free) images are shown in Figure
S2 (Supporting Information).
Figure 4. TEM images of MSN−NH2 (protein-free) particles loaded with 5 nm (top) and 20 nm (bottom) GNP.
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protein-free MSN−NH2 samples show only few GNPs at the
particle surface (Figure S2, Supporting Information). This
indicates that MSN−NH2 particles have very low reactivity
toward GNPs. It should be noted that many reports provide
evidence that amino-coated silica nanoparticles are able to
interact with GNPs,54−58 and indeed, this discrepancy might
be due to GNP size eﬀects. Figure 4 compares MSN−NH2
when reacted with small GNPs (5 nm) and larger GNPs (20
nm), such as those investigated in this work. It appears that
smaller GNPs signiﬁcantly interact with aminopropyl-coated
silica, whereas larger GNPs have scarce aﬃnity for MSN−NH2
(Figure 4).
We recently investigated the formation of the protein corona
on biopolymer (either hyaluronic acid or chitosan) function-
alized MSNs.26 The strategy for its visualization through TEM
was the use of commercial conjugates between the BSA protein
and GNPs. With this method, the black spots in the TEM
images corresponded univocally to the BSA molecules
adsorbed on biopolymer-functionalized MSNs surface. Here,
instead, the proteins were previously immobilized on MSNs
and only then GNPs were left to interact with the MSN−
protein bioconjugates. The TEM images clearly suggest that
large (20 nm) GNPs can interact with MSNs only in the
presence of surface-bound proteins. The diﬀerent reactivities
with GNPs observed for MSN−protein conjugates and MSN−
NH2 control samples suggest the involvement in the
interaction of some speciﬁc amino acid residues occurring at
the protein surface. This deserves a deeper investigation.
2.4. Spectroscopic Investigation of Protein−GNPs
Interactions in Aqueous Solution. Previous studies have
shown that cysteine, lysine, and tryptophan residues can
interact with GNPs.59 Iosin et al. used UV−vis spectroscopy to
verify protein/GNPs interactions60 by monitoring either the
intensity or the position of the localized surface plasmon
resonance band of GNPs at around 420 nm. Winuprasith et al.
used surface-enhanced Raman spectroscopy (SERS) to observe
the enhancement of Raman bands of the amino acid residues
(likely cysteine, tryptophan, etc.) involved in the interaction
with the GNPs.61 Finally, Vaishanav et al. used ﬂuorescence
spectroscopy to investigate protein/GNPs interactions.62
Based on these studies, we used ﬂuorescence spectroscopy to
understand the interaction between GNPs and LYZ or BSA
proteins in aqueous solution. After an excitation with a 250 nm
radiation, the ﬂuorescence spectra of BSA and lysozyme
solutions, at a ﬁxed concentration of 10 mg/mL, were recorded
after addition of increasing volumes of a GNP solution. The
ﬂuorescence spectra, shown in Figure 5, display a peak at the
wavelength 340 nm due to the emission of a tryptophan
residue.60 The addition of GNPs results in a quenching of the
ﬂuorescence intensity. This eﬀect may be ascribed to the
formation of nonﬂuorescent GNPs−protein conjugates (static
quenching), thus suggesting that the tryptophan residues are
involved in the interaction with GNPs.63,64
The ﬂuorescence spectra of GNPs−BSA conjugates undergo
a lower quenching compared to those of GNPs−lysozyme
conjugates, for the same concentration of GNPs. This fact
suggests that the GNPs could display stronger interactions
with lysozyme than with BSA. This diﬀerent interaction may
be due to the structural diﬀerence between the two proteins.
Indeed, lysozyme possesses six tryptophan residues, whereas
BSA only two (Figure 6). Moreover, lysozyme is smaller than
BSA; thus, the odds that such residues are suﬃciently exposed
Figure 5. Fluorescence spectra of (A) BSA/GNPs and (B) LYZ/GNPs aqueous solutions with diﬀerent volume ratios. (C) Raman spectrum of
LYZ/GNPs conjugate solution.
Figure 6. Structure of BSA (PDB ﬁle: 3V03)65 and lysozyme (PDB ﬁle: 1LYZ).66 Tryptophan residues are colored in red. Images obtained with
visual molecular dynamics software.
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to establish an interaction with the GNPs are considerably
higher. This diﬀerent abundances and availability of
tryptophan residues may be the reason why the ﬂuorescence
spectra of GNPs−LYZ conjugates undergo a higher quenching
compared to those of GNPs−BSA conjugates.
The eﬀect of BSA induced by GNPs was studied through
SERS by Iosin et al.67 They found that the occurrence of GNPs
modiﬁes the Raman spectrum of BSA, causing an increase in
the intensity of the bands (SERS eﬀect) of tryptophan
residues. This again conﬁrms that tryptophan is signiﬁcantly
involved in the interaction with GNPs. Figure 5C shows the
Raman spectrum of lysozyme solution compared to that
obtained after the addition of GNPs. Similar to what was
observed for BSA,67 also for lysozyme the Raman signals of
tryptophan are enhanced in the presence of GNPs (Figure
5C). Even other signals turned out to be enhanced, at 1583
and 1616 cm−1, which are, respectively, related to phenyl-
alanine and tyrosine.68 Nevertheless, this fact may likely be due
only to the spatial proximity of the latter residues to some
tryptophan amino acids. Remarkably, ﬁndings from diﬀerent
techniques converge to very similar conclusions.
3. CONCLUSIONS
In this work, we have addressed the design of multicomponent
nano-bioconjugates as a mean to expand the range of available
nanostructures for possible biomedical use. In particular, we
have shown that mesoporous silica nanoparticles with a
hexagonal structure could be covalently conjugated to two
relevant proteins, such as bovine serum albumin and lysozyme.
The conjugation with BSA and lysozyme, quantiﬁed by
thermogravimetric analysis, varies the surface properties as
shown by ζ-potential measurements. Protein conjugation also
modiﬁes surface reactivity, enabling eﬀective interaction with
gold nanoparticles. TEM clearly points out that the bare
nanoparticles (MSN−NH2) poorly interact with large (20 nm)
GNPs, as compared to protein-coated MSNs. TEM images of
the MSN−protein−GNP nano-bioconjugates indicate a more
speciﬁc interaction promoted by the protein coating. Indeed,
TEM images of GNPs located on the MSNs surface provide
indirect information on protein surface location. The
promising results obtained for these nano-bioconjugates may
be related to the tryptophan-mediated interaction between
proteins and GNPs, as demonstrated by ﬂuorescence and
Raman spectroscopies. Further work will be needed to
investigate the application of the obtained nano-bioconjugates
in nanomedicine as biocompatible theranostic devices.
4. EXPERIMENTAL SECTION
4.1. Chemicals. Tetraethylorthosilicate (98%), 3-amino-
propyltriethoxysilane (APTES, 97%), glutaraldehyde (50%
aqueous solution w/v), cetyltrimethylammonium bromide,
gold colloid solutions (GNP, average size 20 and 5 nm),
sodium hydroxide (NaOH, 97%), anhydrous toluene (99.8%),
methanol (99.8%), acetone (99%), bovine serum albumin
(BSA), and disodium hydrogen phosphate (≥99%) were
purchased from Sigma-Aldrich. Sodium dihydrogen phosphate
was purchased from J.T. Baker.
4.2. Preparation of MSN−Protein−GNPs Nano-Bio-
conjugates. Aminopropyl-functionalized mesoporous silica
nanoparticles (MSN−NH2) were prepared following the
method reported in ref 69. Then, MSN−protein−GNP
nano-bioconjugates were prepared. Preliminary studies were
carried out to ﬁnd the conditions that avoid the formation of
MSN aggregates. A mass of 20 mg of MSN−NH2 was
dispersed in 2 mL of 0.1 M phosphate buﬀer at pH 8 with the
help of an ultrasonic bath. A volume of 8 μL of glutaraldehyde
(GA) was then added, and the mixture obtained was left under
mild rotation (60 rpm) for 45 min. The suspension was
centrifuged (4500 rpm for 15 min), and the liquid phase was
removed from the solid through a Pasteur pipette. The
remaining solid (MSN−GA) was washed twice with phosphate
buﬀer solution (0.1 M at pH 8), dispersed under vigorous
stirring and then recovered by centrifugation (4500 rpm for 15
min), and then suspended in the protein solution prepared in
phosphate buﬀer (0.1 M at pH 8). In the case of lysozyme, 3
mL of a 5 mg/mL lysozyme solution was used, whereas 1.5 mL
of a 10 mg/mL was used for BSA. The suspension was left
under mild rotation (60 rpm) overnight. After centrifugation
(4500 rpm for 15 min), the retrieved solid fraction was washed
twice with phosphate buﬀer solution (0.1 M at pH 8) and
dried under vacuum. The complete MSN−protein−GNP
nano-bioconjugates were assembled by adding 700 μL of
colloidal gold solution to 2 mg of obtained MSN−protein
conjugates and leaving the dispersion under rotation (60 rpm)
overnight. Then, the liquid fraction was removed after
centrifugation (4500 rpm for 15 min). The recovered solid
was dried under vacuum and observed by transmission
electron microscopy.
4.3. Physicochemical Characterization of MSNs,
MSN−Protein, and MSN−Protein−GNP Samples. The
structure of MSN−NH2 was veriﬁed by SAXS, whereas speciﬁc
surface area and pore size distribution were obtained by N2
adsorption/desorption isotherms at 77 K recorded on a
Micromeritics ASAP2020 using the Brunauer−Emmett−Teller
(BET) and Barrett−Joyner−Halenda methods,70 respectively.
Transmission electron microscopy (TEM) images were
recorded on a Hitachi H-7000 equipped with a thermionic
W ﬁlament running at 100 kV. Images were collected by a
AMT DVC (2048 × 2048 pixel) CCD camera. Samples for
observation were obtained by direct deposition of the ﬁnely
ground powders on a carbon-coated copper grid. Additional
investigation was performed on a JEM 1400 Plus TEM
microscope. Thermogravimetric analysis (TGA) was carried
out through a Mettler Toledo TGA/SDTA 851. The scans
were collected under oxygen as a reactive gas and nitrogen as a
carrier gas in the range 25−1000 °C. FTIR spectra were
obtained through a Bruker Tensor 27 spectrometer equipped
with a Platinum-ATR accessory and a DTGS (deuterated
triglycine sulfate) detector. ζ-Potential (ζ) of MSNs was
measured using a Zetasizer Nano ZSP (Malvern Instruments)
in backscatter conﬁguration (θ = 173°), at a laser wavelength
of λ = 633 nm. The scattering cell temperature was ﬁxed at 25
°C, and the data were analyzed with the Zetasizer software
7.03 version. The sample was prepared by suspending MSNs
(1 mg/mL) in 0.1 M citrate buﬀer solution and 0.1 M
phosphate buﬀer solution to obtain the ζ-potential values at
pH 4 and pH 7, respectively. Samples were sonicated for 30
min and left under stirring overnight, and then electrophoretic
mobility measurements were carried out. ζ-Potential values
were calculated by means of the Henry equation using water as
the dispersant medium (εr = 78.5 and η = 0.89 cP at 25 °C)
and f(κa) = 1.5 (Smoluchowski approximation).
4.4. Spectroscopic Characterization of GNP−Protein
Conjugates. GNP−protein conjugates were prepared by
adding to 500 μL of 10 mg/mL protein solution in 0.1 M
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phosphate buﬀer at pH 7 increasing amounts of GNPs solution
(50, 100, and 200 μL). The photoluminescence (PL) spectra
of the conjugates with diﬀerent GNP−protein ratios thus
obtained were recorded by exciting GNP−protein samples
with the emission at 250 nm of an optical parametric oscillator
with a frequency doubler device (Spectra Physics MOPO),
seeded by a pulsed Nd-YAG laser (Spectra Physics Quanta Ray
PRO-270). The excitation pulse energy was of about 1 mJ/
pulse, and pulse-width at half-maximum was 8 ns with 10 Hz
repetition rate. PL measurements were performed in back-
scattering geometry, focusing the emitted light signal onto the
entrance slit of a monochromator (ARC Spectra Pro 300i)
with a spectral bandwidth of 12 nm. The signal was detected
by a gatable intensiﬁed CCD (Princeton Instruments PIMAX).
Raman scattering measurements were carried out in back-
scattering geometry with the 632 nm line of a He−Ne laser.
Measurements were performed in air at room temperature with
a triple spectrometer Jobin−Yvon Dilor integrated system with
a spectral resolution of about 1 cm−1.
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Nanoparticles in Injectable Hydrogels: Factors Influencing Cellular
Uptake and Viability. Nanoscale 2017, 9, 12379−12390.
(44) Huang, X.; El-Sayed, I. H.; Qian, W.; El-Sayed, M. A. Cancer
Cell Imaging and Photothermal Therapy in the near-Infrared Region
by Using Gold Nanorods. J. Am. Chem. Soc. 2006, 128, 2115−2120.
(45) Xie, J.; Lee, S.; Chen, X. Nanoparticle-Based Theranostic
Agents. Adv. Drug Delivery Rev. 2010, 62, 1064−1079.
(46) Chanana, M.; Gil, P. R.; Correa-duarte, M. A.; Liz-Marzan, L.
M.; Parak, W. J. Physicochemical Properties of Protein-Coated Gold
Nanoparticles in Biological Fluids and Cells before and after
Proteolytic Digestion. Angew. Chem., Int. Ed. 2013, 52, 4179−4183.
(47) Wang, X.; Tan, L.-L.; Li, X.; Song, N.; Li, Z.; Hu, J.-N.; Cheng,
Y.-M.; Wang, Y.; Yang, Y.-W. Smart Mesoporous Silica Nanoparticles
Gated by Pillararene-Modified Gold Nanoparticles for on-Demand
Cargo Release. Chem. Commun. 2016, 52, 13775−13778.
(48) Zhan, Q.; Qian, J.; Li, X.; He, S. A Study of Mesoporous Silica-
Encapsulated Gold Nanorods as Enhanced Light Scattering Probes for
Cancer Cell Imaging. Nanotechnology 2010, 21, No. 055704.
(49) Li, L.; Wang, H. Enzyme-Coated Mesoporous Silica Nano-
particles as Efficient Antibacterial Agents In Vivo. Adv. Healthcare
Mater. 2013, 2, 1351−1360.
(50) Lee, W.; Park, E. J.; Kwak, S.; Kim, Y.; Na, D. H.; Bae, J. S.
PEGylated Lysozymes with Anti-Septic Effects in Human Endothelial
Cells and in Mice. Biochem. Biophys. Res. Commun. 2015, 459, 662−
667.
(51) Koutsopoulos, S.; Unsworth, L. D.; Nagai, Y.; Zhang, S.
Controlled Release of Functional Proteins through Designer Self-
Assembling Peptide Nanofiber Hydrogel Scaffold. Proc. Natl. Acad.
Sci. U.S.A. 2009, 106, 4623−4628.
(52) Rabbani, G.; Ahmad, E.; Khan, M. V.; Ashraf, M. T.; Bhat, R.;
Khan, R. H. Impact of Structural Stability of Cold Adapted Candida
Antarctica Lipase B (CaLB): In Relation to pH, Chemical and
Thermal Denaturation. RSC Adv. 2015, 5, 20115−20131.
(53) Piludu, M.; Medda, L.; Monduzzi, M.; Salis, A. Gold
Nanoparticles: A Powerful Tool to Visualize Proteins on Ordered
Mesoporous Silica and for the Realization of Theranostic Nano-
bioconjugates. Int. J. Mol. Sci. 2018, 19, 1991.
(54) Perro, A.; Meunier, F.; Schmitt, V.; Ravaine, S. Production of
Large Quantities of “Janus” nanoparticles Using Wax-in-Water
Emulsions. Colloids Surf., A 2009, 332, 57−62.
(55) Phonthammachai, N.; Kah, J. C. Y.; Jun, G.; Sheppard, C. J. R.;
Olivo, M. C.; Mhaisalkar, S. G.; White, T. J. Synthesis of Contiguous
Silica - Gold Core - Shell Structures: Critical Parameters and
Processes. Langmuir 2008, 24, 5109−5112.
(56) Jankiewicz, B. J.; Jamiola, D.; Choma, J.; Jaroniec, M. Silica −
Metal Core − Shell Nanostructures. Adv. Colloid Interface Sci. 2012,
170, 28−47.
(57) Choma, J.; Dziura, A.; Jamioła, D.; Nyga, P.; Jaroniec, M.
Physicochemical and Engineering Aspects Preparation and Properties
of Silica − Gold Core − Shell Particles. Colloids Surf., A 2011, 373,
167−171.
(58) Westcott, S. L.; Oldenburg, S. J.; Lee, T. R.; Halas, N. J.
Formation and Adsorption of Clusters of Gold Nanoparticles onto
ACS Omega Article
DOI: 10.1021/acsomega.9b01240
ACS Omega 2019, 4, 11044−11052
11051
Functionalized Silica Nanoparticle Surfaces. Langmuir 1998, 14,
5396−5401.
(59) Brewer, S. H.; Glomm, W. R.; Johnson, M. C.; Knag, M. K.;
Franzen, S. Probing BSA Binding to Citrate-Coated Gold Nano-
particles and Surfaces. Langmuir 2005, 21, 9303−9307.
(60) Iosin, M.; Canpean, V.; Astilean, S. Spectroscopic Studies on
pH- and Thermally Induced Conformational Changes of Bovine
Serum Albumin Adsorbed onto Gold Nanoparticles. J. Photochem.
Photobiol., A 2011, 217, 395−401.
(61) Winuprasith, T.; Suphantharika, M.; McClements, D. J.; He, L.
Spectroscopic Studies of Conformational Changes of β-Lactoglobulin
Adsorbed on Gold Nanoparticle Surfaces. J. Colloid Interface Sci. 2014,
416, 184−189.
(62) Vaishanav, S. K.; Chandraker, K.; Korram, J.; Nagwanshi, R.;
Ghosh, K. K.; Satnami, M. L. Protein Nanoparticle Interaction: A
Spectrophotometric Approach for Adsorption Kinetics and Binding
Studies. J. Mol. Struct. 2016, 1117, 300−310.
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